Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

CDC panel: Healthcare workers and nursing home residents should be among first to get COVID-19 vaccine

By Brian Buntz | December 1, 2020

A Centers for Disease Control and Prevention (CDC) advisory panel voted 13 to 1 to prioritize COVID-19 vaccines for healthcare workers and residents of long-term facilities after FDA authorizes their use.  

The panel’s recommendations include three-tiers — Phases 1A, 1B and 1C — for early vaccinations. Officials with the federal government’s Operation Warp Speed have said that state governments will choose who gets COVID-19 vaccines first, but CDC guidance will weigh heavily on the decisionmaking. 

Phase 1A will be the first group. 

Potentially next in line for the vaccines will be essential workers, people with high-risk medical conditions and adults 65 or older, who would fall under Phase 1B in a CDC proposed grouping. 

More than 260 million Americans would fall under the broader proposed Phase 1 vaccination scheme, including 87 non-healthcare workers, more than 100 million adults with high-risk medical conditions and 53 million seniors. “The elderly are much more likely to get severe disease and die,” said epidemiologist Megan Murray in a conversation with Elana Gordon, a journalist at The World. By contrast, the rate of COVID-19 infection among healthcare workers has been lower than expected, Murray said.  

Healthcare workers have a significant risk of contracting the novel coronavirus. As of Nov 21., at least 228,503 healthcare workers had been sickened by the virus. Among them were 822 deaths.

The CDC Advisory Committee on Immunization Practices (ACIP) panel has held a series of meetings since the beginning of the pandemic to discuss topics ranging from vaccine prioritization to adverse event monitoring. 

A vaccine could be available in the coming weeks. Both Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) have filed for emergency use authorization for their respective SARS-CoV-2 vaccines. 

The vaccine might not be broadly available until April, May or June of next year, according to the epidemiologist Murray.


Filed Under: Drug Discovery, Infectious Disease
Tagged With: CDC, coronavirus, covid-19, COVID-19 vaccine, FDA, U.S. Centers for Disease Control and Prevention (CDC)
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech vaccine
U.S. government plans to stop paying for COVID-19 vaccines 
Monkeypox
U.S. to boost supplies of Tpoxx to fight monkeypox outbreak
Pfizer-BioNTech
Next-gen Pfizer-BioNTech vaccine candidates fare well in Phase 2/3 study
covid-19 vaccine
Fall 2022 COVID-19 vaccine candidate tracker

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50